Artículos del autor

solaci

Antithrombotic Anticoagulants

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in...
solaci -
Bifurcations

Three-Year Outcomes after CTA with 2-Stent Technique Vs. Provisional Stenting for Complex Bifurcation Lesions

The prevalence of coronary lesions with bifurcation involvement is about 20% in patients undergoing coronary angiography (CTA)....
solaci -
Institutional News

Watch again Disruptive and Conventional Treatments Below The Knee and in the Superficial Femoral Artery – SOLACI Webinar

Watch again Disruptive and Conventional Treatments Below The Knee and in the Superficial Femoral Artery on our Youtube...
solaci -
Institutional News

Last Days to Sign Up to SOLACI-SOCIME 2022 with 15% OFF

LAST DAYS TO SIGN UP WITH 15% OFF We are a little less than one month away from the...
solaci -
Coronary disease

Same Day Discharge in NSTE-ACS: Is It Possible?

At present, percutaneous coronary intervention (PCI) is the most common coronary revascularization strategy. One of its benefits...
solaci -
Femoral

Thromboendarterectomy vs. Endovascular Therapy in Common Femoropopliteal Territory. Is Surgery Still the Gold Standard?

For lesions in the common femoral artery, guidelines recommend surgical endarterectomy (TEA) as the gold standard. However,...
solaci -
Femoropopliteal

Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and...
solaci -
Institutional News

12/07 | SOLACI Webinar – Disruptive and Conventional Treatments in the SFA and BTK – Register Now

solaci -